

Barcelona, October 2nd 2018

SIGNIFICANT EVENT

Almirall receives FDA approval for SEYSARA™ (sarecycline)

Almirall S.A (“Almirall”), pursuant to article 228 of the restated text of the Securities Market Act approved by the Royal Legislative Decree 4/2015, of 23 October and related provisions, hereby announces:

On October 1st 2018, the FDA (U.S. Food and Drug Administration) approved SEYSARA™ (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.

SEYSARA (sarecycline) is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the potential treatment of moderate to severe acne.

This new product comes from Allergan U.S. medical dermatology acquisition and its approval is ahead of plan.

Almirall will be launching Seysara in January 2019 in the US market and expects peak sales of Seysara™ (sarecycline) between \$150MM to \$200MM.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations & Corporate Comms. Department
investors@almirall.com